🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very fortunate to present our work at the largest cancer research conference for more than 61k clinicians.

We are excited about our new work "Identifying Immune determinants of the association between Tumor mutational burden and Immune checkpoint response across cancer types". Had a lot of fun and learned a lot during the process of this work with Sanju Sinha (co-first author)

This effort was lead by NEELAM SINHA (& Sanju Sinha) whose talk on this at AACR 2021 can be found here aacr.org/about-the-aacr…

A nice highlight in Cancer Discovery Cancer Discovery of our approach for predicting treatment responses via the tumor transcriptome Joo Sang Lee National Cancer Institute @NCIResearchCtr cancerdiscovery.aacrjournals.org/content/early/…

Odds ratio and Fisher tests are nicely explained here: #statisticalanalysis lnkd.in/euy-YQns

Why high tumor mutation burden is only predictive of immunotherapy response in some cancer types? We answer this question in our latest publication below and are excited to share it here. A🧵of 🏄‍♀️ below. aacrjournals.org/cancerres/arti…

I am looking for a bioinformatics/data scientist position in the healthcare sector in an exciting team. 🤩 Drop a message if you have a position and are interested to chat. My messages are open. 😇 #AcademicTwitter #Bioinformatics #Jobs My latest work x.com/NCIEytanRuppin…

Excited to attend my 1st in personal conference and learn more about immunotherapy.😃#KSimmunecheckpoints22 If you are attending please stop by my poster "Why high tumor mutation burden is only predictive of Immunotherapy response in some cancer types?" on Saturday June 11th.

Impostor syndrome: “I don't know what I'm doing. It's only a matter of time until everyone finds out." Growth mindset: "I don't know what I'm doing yet. It's only a matter of time until I figure it out." The highest form of self-confidence is believing in your ability to learn.

Drug target identification is at the heart of drug development, and we’ve been working to change how it’s been done. We present DeepTarget: a new computational tool to characterize a drug’s mechanism of action in-depth beyond its primary target. 🧰🧵👇 biorxiv.org/content/10.110…

A lot of Machine Learning (ML) I learned during my Ph.D. was from youtube. I didn't have a guide to do this effectively and thus here it is: A complete guide to studying ML from youtube: 13 best and most recent ML courses available on YouTube. 👩‍🏫🧵⤵️

28 common issues you will likely face while using ML for biomedicine and how to address them. x.com/Sanjusinha7/st…

12 resources to best analyze Spatial Transcriptomics. x.com/Sanjusinha7/st…

10 educational resources for anyone interested in building skills to analyze big data in healthcare. x.com/Sanjusinha7/st…

20 open grand challenges to understand the relationship btw cancer and aging better. x.com/Sanjusinha7/st…

I am developing a drug discovery startup based on a recent computational technology I co-developed (See below). I would love to chat if you would like to collaborate on this or a potential investor. DM/email [email protected] x.com/NCIEytanRuppin…

With a mixed bag of emotions - nervousness, excitement, fear & determination, I am announcing the start of my lab at Sanford Burnham Prebys, San Diego. Our focus will be to develop new preventative therapies for cancer using machine learning.

I am hiring multiple Computational Biologists for my new lab Sanford Burnham Prebys , San Diego. An alternative to a postdoc, it will pay higher (70-90K$; Be the change you want to see in the world) & is tailored to develop skills to industry transition. linkedin.com/jobs/view/3677… My lab

We don't yet have a way to guide therapy decisions with single-cell omics. Taking one step forward to solve this, we developed a transfer learning method for patient stratification & resistance emergence to targeted therapies using sc-omics & validated in 3 trials. 🧵

Aging physically reshapes our tissues, and we know very little about it. We found that an aging hallmark - Telomere Shortening - leaves imprints on tissue architecture that can be captured in routine H&E images and can predict telomere length.